I respond to biotech companies that reach out for software engineering positions by offering them our software instead, which has led to converting users into paid customers.

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

We received a ray of hope when Y Combinator reached out to us, as they were looking to support more hardware companies.

Biotech companies often use their time in Y Combinator to conduct critical path experiments and work with external companies for proof of concept studies, which can advance their regulatory filing status.

The last few years have been sobering for the biotech industry, highlighting the need to adapt quickly to survive amidst fierce competition for attention from investors, partners, and talent.

Biotech and medical device companies have shown success in the YC program, benefiting from focused milestones during the three-month period.

Focusing on biopharma companies as a target market allows for a more tailored data solution that meets their specific needs.

There is a growing interest from early-stage technology investors in funding biotech companies, with many successfully raising significant seed funding.

Successful biotech funds often incubate ideas internally before spinning them out as independent companies, which has proven effective in the industry.